← Leaderboards
Jeffrey Statland
University Of Rochester
$2,955,030
Attributed
$6,953,519
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,058,295 · 4
ATSDR$895,224 · 1
By mechanism
U01$5,497,625 · 2
R01$895,224 · 1
R21$452,355 · 1
U54$108,315 · 1
Top collaborators
- Rabi Tawil6 shared
- Katy Eichinger3 shared
- Seth David Friedman3 shared
- Xing Song3 shared
- Ian Woodcock3 shared
- Nicholas Elwood Johnson2 shared
Most similar at University Of Rochester
Same institution · by research overlap
- Rabi Tawil$9,728,744
- Richard T Moxley$13,171,275
- Robert H Dworkin$7,813,753
- Erika Augustine$6,110,416
- David N Herrmann$7,677,030
Others in their field
Other Emerging Leaders on “Clinical Trials”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$245,363,765
- Beth Baseler · Leidos Biomedical Research, Inc.$207,964,226
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$177,411,785
Research focus
Clinical TrialsDisease ProgressionTargeted TreatmentFutureSiteCohortProgramsProspectiveCharacteristicsMuscleTrainingReportingFacioscapulohumeral Muscular DystrophyMuscular DystrophiesPharmaceutical PreparationsBurden Of IllnessSpinal Muscular AtrophySubgroupBiological MarkersMotorMeetingsDuchenne Muscular DystrophyCross-Sectional StudiesParticipant
Grant awards (15)
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)$995,267
U01 · FY2025 · NS · contact PI
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)$123,916
U01 · FY2025 · NS · contact PI
Career Enhancement$108,315
U54 · FY2025 · NS · contact PI
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)$1,184,364
U01 · FY2024 · NS · contact PI
RFA-TS-22-001:Towards Better Understanding of ALS using a Multi-Marker Discovery Approach from a Multi-Modal Database (ALS4M)$295,573
R01 · FY2024 · TS
Towards Better Understanding of ALS using a Multi-Marker Discovery Approach from a Multi-Modal Database (ALS4M)$299,753
R01 · FY2023 · TS
Towards Better Understanding of ALS using a Multi-Marker Discovery Approach from a Multi-Modal Database (ALS4M)$299,898
R01 · FY2022 · TS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$47,505
U01 · FY2022 · NS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$405,568
U01 · FY2021 · NS
Development and validation of clinical outcome assessments in LGMD2A$198,181
R21 · FY2021 · TR
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$550,880
U01 · FY2020 · NS
Development and validation of clinical outcome assessments in LGMD2A$254,174
R21 · FY2020 · TR
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$899,778
U01 · FY2019 · NS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$778,289
U01 · FY2018 · NS
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD$512,058
U01 · FY2017 · NS